1. Scrip
  2. >>Therapy Areas
  3. >>Blood and Clotting

Alexion's Defensive Play Poised To Pay Off

 
• By Jessica Merrill

The company's long-acting C5 complement inhibitor ALXN1210 demonstrated non-inferiority to Soliris in a Phase III trial, which should help the company defend against anticipated competition to its blockbuster franchise.

chess

Alexion Pharmaceuticals Inc. scored an important win for its defensive strategy on its all-important Soliris (eculizumab) franchise. The firm's next-generation long-acting C5 complement inhibitor, ALXN1210, performed as well as Soliris in a Phase III clinical trial in treatment-naïve patients with paroxysmal nocturnal hemoglobinuria (PNH) dosed every eight weeks, versus every two-week dosing for Soliris.

Management said it is on track to submit regulatory filings for ALXN1210 in the US, Europe and Japan in the second half of 2018. The company is awaiting data from...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Blood and Clotting

In Brief: Bioxodes To Take Novel Hemorrhagic Stroke Drug Into Registrational Trial

 
• By Sushmita Panda

The Belgium-based firm will take the first-in-class drug, based on tick saliva, targets inflammation without increasing bleeding, into a Phase IIb trial is in preparation, supported by a new series B funding round.

Sanofi Spends Big In US But Offers Crumbs Of Comfort For Europe

 
• By Kevin Grogan

CFO François Roger tells Scrip the French drugmaker is flexible geographically on making investments but its spend in the US has risen regardless of the threat of tariffs.

Sanofi Set To Shake Up Crowded Hemophilia Space After Qfitlia Approval

 
• By Kevin Grogan

The small interference RNA therapeutic can be used by patients regardless of inhibitor status.

With Phase III Success, PharmaEssentia To Seek Besremi Label Expansion (Update)

 
• By Joseph Haas

Taiwan-based PharmaEssentia hopes to add essential thrombocytopenia to the label for its pegylated interferon product, already approved to treat polycythemia vera.

More from Therapy Areas

Senti’s Computer-Logic Inspired Cell Therapy Shows Early Promise

 
• By Andrew McConaghie

The biotech believes its logic-gated cell therapies can get round the need for ‘clean targets’ which limit CAR-Ts and ADCs.

All Over For iTeos But Applause For Plan To Return Cash Fast

 
• By Kevin Grogan

The company has moved quickly to wind down operations after its anti-TIGIT pact with GSK collapsed.

In Brief: Nicox Extends Cash Runway As Kowa Advances NCX 470 In Japan

 
• By Sushmita Panda

Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.